Drug intelligence / Profile preview

PKX-001

Development stage: Phase 1
Lead developer: ProtoKinetix

Overview

PKX-001 is a glycopeptide, also referred to as an anti-aging glycoprotein (AAGP®), developed by ProtoKinetix. It is being investigated for its cardioprotective properties and its ability to enhance the health and survival of beta cells for transplantation, particularly in the context of type 1 diabetes. The drug aims to improve the durability of islet transplants and protect against the toxic effects of immunosuppressants like tacrolimus.

Brand names: AAGPAAGP™
Other names: AAGP®AAGP™

Targets

SELL (L-selectin)

Beyond the preview

Go deeper on PKX-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PKX-001.

Explore the full profile